Evernest Financial Advisors LLC Invests $374,000 in Precipio, Inc. $PRPO

Evernest Financial Advisors LLC bought a new stake in shares of Precipio, Inc. (NASDAQ:PRPO) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 21,000 shares of the biotechnology company’s stock, valued at approximately $374,000. Evernest Financial Advisors LLC owned 1.30% of Precipio at the end of the most recent reporting period.

Separately, AMH Equity Ltd grew its position in Precipio by 370.1% during the 3rd quarter. AMH Equity Ltd now owns 131,100 shares of the biotechnology company’s stock worth $2,332,000 after purchasing an additional 103,210 shares during the period. Institutional investors and hedge funds own 10.45% of the company’s stock.

Analyst Ratings Changes

PRPO has been the topic of a number of recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Precipio in a research note on Thursday, January 22nd. Wall Street Zen raised Precipio to a “hold” rating in a report on Saturday, February 14th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has an average rating of “Sell”.

Precipio Stock Up 1.9%

Precipio stock opened at $25.16 on Wednesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.27 and a quick ratio of 1.10. The stock has a market capitalization of $44.03 million, a PE ratio of -30.68 and a beta of 1.22. The business has a 50 day simple moving average of $23.64 and a 200-day simple moving average of $21.33. Precipio, Inc. has a 12 month low of $3.90 and a 12 month high of $28.50.

About Precipio

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.